Twist Bioscience UK Ltd 13578466 false 2024-10-01 2025-09-30 2025-09-30 The principal activity of the company is research and experimental development on biotechnology. Digita Accounts Production Advanced 6.30.9574.0 true false true 13578466 2024-10-01 2025-09-30 13578466 2025-09-30 13578466 bus:OrdinaryShareClass1 2025-09-30 13578466 core:CurrentFinancialInstruments 2025-09-30 13578466 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 13578466 bus:SmallEntities 2024-10-01 2025-09-30 13578466 bus:Audited 2024-10-01 2025-09-30 13578466 bus:FilletedAccounts 2024-10-01 2025-09-30 13578466 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 13578466 bus:RegisteredOffice 2024-10-01 2025-09-30 13578466 bus:CompanySecretary1 2024-10-01 2025-09-30 13578466 bus:Director2 2024-10-01 2025-09-30 13578466 bus:Director3 2024-10-01 2025-09-30 13578466 bus:OrdinaryShareClass1 2024-10-01 2025-09-30 13578466 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 13578466 core:ParentEntities 2024-10-01 2025-09-30 13578466 1 2024-10-01 2025-09-30 13578466 countries:England 2024-10-01 2025-09-30 13578466 2023-10-01 2024-09-30 13578466 2024-09-30 13578466 bus:OrdinaryShareClass1 2024-09-30 13578466 core:CurrentFinancialInstruments 2024-09-30 13578466 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13578466

Twist Bioscience UK Ltd

Filleted Financial Statements

for the Year Ended 30 September 2025

 

Twist Bioscience UK Ltd

Contents

Company Information

1

Statement of Financial Position

2

Notes to the Financial Statements

3 to 7

 

Twist Bioscience UK Ltd

Company Information

Directors

Robert Werner

Emily Leproust

Company secretary

OHS Secretaries Limited

Registered office

9th Floor
107 Cheapside
London
EC2V 6DN

Auditors

Morris & Young, Statutory Auditor
Chartered Accountants
6 Atholl Crescent
Perth
PH1 5JN

 

Twist Bioscience UK Ltd

(Registration number: 13578466)
Statement of Financial Position as at 30 September 2025

Note

2025
£

2024
£

Current assets

 

Debtors

4

1,189,814

700,699

Cash at bank and in hand

 

253,350

218,488

 

1,443,164

919,187

Creditors: Amounts falling due within one year

5

(674,872)

(347,890)

Net assets

 

768,292

571,297

Capital and reserves

 

Called up share capital

6

100

100

Retained earnings

768,192

571,197

Shareholders' funds

 

768,292

571,297

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 15 June 2026 and signed on its behalf by:
 

.........................................
Robert Werner
Director

.........................................
Emily Leproust
Director

 

Twist Bioscience UK Ltd

Notes to the Financial Statements for the Year Ended 30 September 2025

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
9th Floor
107 Cheapside
London
EC2V 6DN

These financial statements were authorised for issue by the Board on 15 June 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in Sterling (£) and rounded to the nearest £1.

Going concern

The financial statements have been prepared on a going concern basis.

 

Twist Bioscience UK Ltd

Notes to the Financial Statements for the Year Ended 30 September 2025

Audit report

The Independent Auditor's Report was unqualified. . The name of the Senior Statutory Auditor who signed the audit report on 19 June 2026 was Alexander J Fyfe M.A.A.T., C.A., DChA, who signed for and on behalf of Morris & Young, Statutory Auditor.

.........................................

Revenue recognition

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash in hand and on deposit.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

 

Twist Bioscience UK Ltd

Notes to the Financial Statements for the Year Ended 30 September 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Classification
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial liabilities.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 22 (2024 - 18).

 

Twist Bioscience UK Ltd

Notes to the Financial Statements for the Year Ended 30 September 2025

4

Debtors

Current

Note

2025
£

2024
£

Amounts owed by related parties

7

1,124,741

637,579

Prepayments

 

52,895

26,927

Other debtors

 

12,178

36,193

   

1,189,814

700,699

5

Creditors

Creditors: amounts falling due within one year

2025
£

2024
£

Due within one year

Trade creditors

40,091

12,784

Accruals and deferred income

58,950

109,589

Other creditors

575,831

225,517

674,872

347,890

6

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

       

7

Related party transactions

Summary of transactions with parent

The company has taken advantage of exemption, under the terms of FRS 102, not to disclose related party transactions with wholly owned subsidiaries within the group.
 

 

Twist Bioscience UK Ltd

Notes to the Financial Statements for the Year Ended 30 September 2025

8

Parent and ultimate parent undertaking

The company is a wholly owned subsidiary.

 The company's immediate parent is Twist Bioscience Netherlands B.V., incorporated in Amsterdam.

  These financial statements are available upon request from Beechavenue 54, Office 1.06A, 1119PW Schiphol-Rijk.